<div id="readability-page-1"><div><p>(MT Newswires) -- Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index easing 0.01% and the Health Care Select Sector SPDR Fund (XLV) adding 0.1%.</p><p> The iShares Biotechnology ETF (IBB) was shedding 0.5%.</p><p> In corporate news, Amgen's (AMGN) Uplizna has received a positive opinion from the European Medicines Agency's human medicines committee recommending its approval for adults with active immunoglobulin G4-related disease, a rare autoimmune disorder with no authorized treatments in the EU. Amgen shares rose past 3%.</p><p> InterCure (INCR) shares were down 1.4% after it said Friday it has agreed to buy medical cannabis brand and technology company Botanico, also known as ISHI, in a two-phase deal valued at about 10% of InterCure's outstanding shares on a fully-diluted basis.</p><p>ARS Pharmaceuticals (SPRY) shares added nearly 1% after the company said its nasal spray Neffy has received regulatory approval in Japan for the emergency treatment of allergic reactions, including anaphylaxis.</p></div></div>

SPRY

<p>医疗保健股票在周五表现参差不齐，纽约证券交易所医疗保健指数下跌 0.01%，而医疗保健精选行业 SPDR 基金上涨 0.1%。安进的 Uplizna 在欧盟获得了积极的批准意见，推动其股价上涨超过 3%。InterCure 的股价在宣布收购 Botanico 的交易后下跌 1.4%。与此同时，ARS Pharmaceuticals 的股价在其鼻用喷雾剂 Neffy 获得日本监管批准后上涨近 1%</p>

行业更新：周五下午，医疗保健类股表现参差不齐